- Home
- ALT
ALT
Altimmune Inc.
as 06-17-2025 3:30pm EST
Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.
| Founded: | 1997 | Country: | United States |
| Employees: | N/A | City: | GAITHERSBURG |
| Market Cap: | 472.3M | IPO Year: | N/A |
| Target Price: | $21.00 | AVG Volume (30 days): | 3.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.25 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.55 - $11.16 | Next Earning Date: | 08-07-2025 |
| Revenue: | $20,000 | Revenue Growth: | -95.12% |
| Revenue Growth (this year): | -89.19% | Revenue Growth (next year): | 1557547.90% |
Latest Altimmune Inc. News
ALT Breaking Stock News: Dive into ALT Ticker-Specific Updates for Smart Investing
GlobeNewswire
4 days ago
Altimmune Announces Multiple Presentations at Upcoming American Diabetes Association’s Scientific Sessions
GlobeNewswire
a month ago
Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD)
TipRanks
a month ago
Morning Movers: UnitedHealth sinks following CEO exit and outlook suspension
GlobeNewswire
a month ago
Altimmune to Participate at Two Upcoming Investor Conferences
GlobeNewswire
a month ago
Altimmune Announces First Quarter 2025 Financial Results and Business Update
GlobeNewswire
a month ago
Altimmune Secures Up to $100 Million in Credit Facility from Hercules Capital
GlobeNewswire
a month ago
Altimmune Presents New Analyses Predicting High Rates of MASH Resolution on Biopsy following Pemvidutide Treatment at the EASL International Liver Congress™
GlobeNewswire
a month ago
Altimmune to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025
Compare ALT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ALT Altimmune Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.